Clinical trial branding? Biotechs and pharmas migrate name and identity strategies even earlier
Branding is moving more and more downstream into clinical trials. Biotech and pharma companies are thinking about drug brand product names and identities much sooner in the development process, but there’s also another trend brewing in early marketing strategies — clinical trial branding.
With drug development focusing in on more rare diseases and smaller patient populations, biopharmas are fighting for mindshare and looking for a way to stand out to patients and healthcare professionals. And that’s where Phase II clinical trial branding is starting to fire up.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.